Downregulation of Sec23A Protein by miRNA-375 in Prostate Carcinoma

Prostate carcinoma (CaP) is a leading cause of cancer-related death in men. We have previously determined the microRNA (miRNA) profile of primary CaP in comparison with nontumor prostate tissue. miRNAs are small, noncoding RNAs that inhibit protein synthesis on a posttranscriptional level by binding to the 3′-untranslated region (3′-UTR) of their target genes. In primary CaP tissue, we have previously found by miRNA sequencing that miR-375 and miR-200c were upregulated 9.1- and 4.5-fold, respectively. A computational analysis predicted the 3′-UTR of the SEC23A gene as a potential target for both miR-375 and miR-200c. Here, we show that the 3′-UTR of SEC23A mRNA is indeed a target for miR-375 and miR-200c and that both miRNAs downregulate Sec23A protein expression when ectopically expressed in human 293T cells. In primary samples of CaP, we found a direct correlation between reduction of SEC23A mRNA and overexpression of miR-375 but not of miR-200c. The reduced levels of Sec23A protein were inversely correlated to the increased amount of miR-375 in the LNCaP and DU145 CaP cell lines when compared with normal prostate fibroblasts. In primary CaP, we also detected decreased amounts of Sec23A protein when compared with corresponding normal prostate tissue. Ectopically overexpressed Sec23A in LNCaP and DU145 CaP cells significantly reduced the growth properties, indicating that Sec23A might play a role in the induction or growth of prostate carcinoma. Sec23A overexpression reduced cell growth but did not induce apoptosis, whereas inhibition of Sec23A stimulated cell proliferation. Mol Cancer Res; 9(6); 791–800. ©2011 AACR.

[1]  Dieter Jocham,et al.  A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. , 2010, Urologic oncology.

[2]  A. Schetter,et al.  MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival , 2009, Clinical Cancer Research.

[3]  P. Falkai,et al.  The LARK/RBM4a protein is highly expressed in cerebellum as compared to cerebrum , 2008, Neuroscience Letters.

[4]  J. Steitz,et al.  Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR , 2007, Proceedings of the National Academy of Sciences.

[5]  Gunter Meister,et al.  miRNAs Get an Early Start on Translational Silencing , 2007, Cell.

[6]  Arndt Hartmann,et al.  The MicroRNA Profile of Prostate Carcinoma Obtained by Deep Sequencing , 2010, Molecular Cancer Research.

[7]  B. Seliger,et al.  Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer , 2010, Cancer Immunology, Immunotherapy.

[8]  H. Trompeter,et al.  Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells , 2010, BMC Research Notes.

[9]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[10]  C. Croce,et al.  SnapShot: MicroRNAs in Cancer , 2009, Cell.

[11]  R. Aharonov,et al.  A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. , 2010, The Journal of molecular diagnostics : JMD.

[12]  Enrica Calura,et al.  Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. , 2011, The Lancet. Oncology.

[13]  Yvonne Tay,et al.  MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation , 2008, Nature.

[14]  Y. Lu,et al.  Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  W. Criekinge,et al.  The N‐myc downstream regulated gene (NDRG) family: diverse functions, multiple applications , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  Arif B Ekici,et al.  MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening , 2012, International journal of cancer.

[17]  Y. Jun,et al.  Receptor‐Mediated ER Export of Human MHC Class I Molecules Is Regulated by the C‐Terminal Single Amino Acid , 2011, Traffic.

[18]  Jianmin Si,et al.  MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2 , 2010, Cell Research.

[19]  M. Okoniewski,et al.  microRNA profiling in Epstein–Barr virus-associated B-cell lymphoma , 2010, Nucleic acids research.

[20]  K. Ohuchida,et al.  MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation , 2010, Molecular Cancer.

[21]  C. Croce,et al.  Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. , 2010, Cancer research.

[22]  P. Stern,et al.  Loss of HLA class I expression in prostate cancer: implications for immunotherapy. , 1995, Urology.

[23]  Randy Schekman,et al.  Coordination of COPII vesicle trafficking by Sec23. , 2008, Trends in cell biology.

[24]  J. Christopher Fromme,et al.  The genetic basis of a craniofacial disease provides insight into COPII coat assembly. , 2007, Developmental cell.

[25]  R. Schekman,et al.  COPII: A membrane coat formed by Sec proteins that drive vesicle budding from the endoplasmic reticulum , 1994, Cell.

[26]  H. Allgayer,et al.  Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non–Small Cell Lung Cancer , 2010, Molecular Cancer Research.

[27]  David J. Stephens,et al.  Assembly, organization, and function of the COPII coat , 2007, Histochemistry and Cell Biology.

[28]  Norbert Senninger,et al.  EP300—A miRNA‐regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas , 2010, International journal of cancer.

[29]  K. Roemer,et al.  Epstein–Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5 , 2007, Nucleic acids research.

[30]  M. Seto,et al.  MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. , 2010, Cancer research.

[31]  Laura Pelletier,et al.  MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations , 2008, Hepatology.

[32]  Brock C Christensen,et al.  MicroRNA Expression Ratio Is Predictive of Head and Neck Squamous Cell Carcinoma , 2009, Clinical Cancer Research.

[33]  E. Howe,et al.  Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers , 2009, Journal of oncology.

[34]  R. Schekman,et al.  Cloning and functional characterization of mammalian homologues of the COPII component Sec23. , 1996, Molecular biology of the cell.

[35]  M. Frotscher,et al.  Secretory COPII coat component Sec23a is essential for craniofacial chondrocyte maturation , 2006, Nature Genetics.

[36]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[37]  G. Hurteau,et al.  Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression , 2009, Cell cycle.

[38]  C. Tepper,et al.  microRNAs and prostate cancer , 2008, Journal of cellular and molecular medicine.